Hetlioz

Chemical Nametasimelteon
Dosage FormCapsule, suspension (oral; 20mg, 4mg/ml)
Drug ClassReceptor agonists
SystemEndocrine
CompanyVanda Pharmaceuticals Inc.
Approval Year2014

Indication

  • Oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age.
  • Capsules are indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in adults and Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Hetlioz (tasimelteon) Prescribing Information2014Vanda Pharmaceuticals Inc. Washington, D.C.